Format

Send to

Choose Destination
BMJ Case Rep. 2019 Aug 1;12(7). pii: e229456. doi: 10.1136/bcr-2019-229456.

Supervised injectable opioid agonist therapy in a supported housing setting for the treatment of severe opioid use disorder.

Author information

1
Family Practice, University of British Columbia, Vancouver, British Columbia, Canada.
2
Medicine, University of British Columbia, Vancouver, British Columbia, Canada.

Abstract

Currently, North America is facing a national opioid overdose crisis. Opioid use disorder (OUD) is a chronic, relapsing condition requiring varying intensities of treatment. Injectable opioid agonist therapy (iOAT) is an effective, high-intensity treatment option for people who are unsuccessful on conventional oral opioid agonist treatments (eg, methadone, buprenorphine). This case highlights the effectiveness of the provision of iOAT in a low-barrier setting. More specifically, we discuss a patient with severe OUD and untreated HIV infection, who was disengaged from medical care and, consequently, was prescribed iOAT in a supportive housing setting.

KEYWORDS:

HIV/AIDS; drug misuse (including addiction); general practice / family medicine

PMID:
31371332
DOI:
10.1136/bcr-2019-229456

Conflict of interest statement

Competing interests: None declared.

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center